{"analyses":[{"ciLowerLimit":"-27.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-15.52","estimateComment":"LS Mean: Osimertinib -46.93, Chemo -25.3 A difference in LS means \\<0 favours Osimertinib 80mg","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","paramType":"Difference in LS means","paramValue":"-21.62","statisticalComment":"Covariates for ethnicity (Asian, non-Asian) and the baseline sum of diameters of target lesions","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.50","value":"-46.1"},{"groupId":"OG001","spread":"29.27","value":"-24.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"278"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Tumour size was calculated as the sum of the longest diameters (SLD) of the Target Lesions. Tumour shrinkage is percentage change in tumour size from baseline using RECIST v1.1 tumour response.","dispersionType":"Standard Deviation","groups":[{"description":"Daily single dose of Osimertinib 80mg","id":"OG000","title":"Osimertinib 80mg"},{"description":"Platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"Full Analysis Set (All randomised patients)","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).","title":"Tumour Shrinkage by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"% change from baseline"}